Finanzen von Recursion Pharmaceuticals Inc (RXRX)RXRXRecursion Pharmaceuticals Inc

Evaluating the bottom line, Recursion Pharmaceuticals, Inc. maintains a gross margin of -49.82%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1759.69%, while the net margin is -1708.02%. These profitability ratios, combined with a Return on Equity (ROE) of -56.58%, provide a clear picture of how effectively RXRX converts its operational activities into shareholder value.

In the context of the broader market, RXRX competes directly with industry leaders such as NTLA and SEPN. With a market capitalization of $1.78B, it holds a significant position in the sector. When comparing efficiency, RXRX's gross margin of -49.82% stands against NTLA's 100.00% and SEPN's 100.00%. Such benchmarking helps identify whether Recursion Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Recursion Pharmaceuticals reported a total revenue of 7.67 million USD for Q2 2026, but continues to face significant net losses, with a net income of -131 million USD. The gross margin for the same period is -49.82%, indicating challenges in profitability.